Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SGX:9CI
SGX:9CIReal Estate

CapitaLand Investment (SGX:9CI) Valuation Check After FY2025 Earnings And New Asia Subsidiaries

Earnings and new subsidiaries set the tone for CapitaLand Investment (SGX:9CI) CapitaLand Investment (SGX:9CI) has been in focus after its full year 2025 earnings showed sales of S$2,133 million and net income of S$145 million, along with wide ranging subsidiary incorporations across Asia. See our latest analysis for CapitaLand Investment. The earnings release and new subsidiaries land against a backdrop of a 16.9% 90 day share price return and a 33.4% 1 year total shareholder return. By...
NasdaqGS:TPG
NasdaqGS:TPGCapital Markets

Is It Time To Reassess TPG (TPG) After A 26% One Month Share Price Slide

If you are wondering whether TPG’s share price reflects its underlying worth right now, you are not alone. This article is here to frame the key valuation questions you might be asking. After reaching a recent close of US$49.53, the stock has seen a 10% decline over the last 7 days and a 26.2% decline over the last 30 days, while still showing a 64.5% return over 3 years and mixed results over shorter periods including year to date and the last 12 months. Recent news coverage around TPG has...
NasdaqCM:ONCY
NasdaqCM:ONCYBiotechs

Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant mCRC Regimen

On February 4, 2026, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant, microsatellite-stable metastatic colorectal cancer. The designation is backed by clinical data showing pelareorep-based therapy delivered higher response rates and longer survival measures than existing standard-of-care options in this hard-to-treat subgroup. With the FDA’s Fast Track Designation in place,...
NasdaqGS:DKNG
NasdaqGS:DKNGHospitality

DraftKings (DKNG) Q4 Profitability Upswing Tests Bullish Earnings Narratives

DraftKings (DKNG) closed out FY 2025 with Q4 revenue of US$1.99b and basic EPS of US$0.28, while trailing twelve month EPS edged into positive territory at US$0.01 on revenue of US$6.05b. This helped set the tone for a results season where profitability is firmly in focus. The company has seen quarterly revenue move from US$1.39b in Q4 2024 to US$1.99b in Q4 2025, with basic EPS shifting from a loss of US$0.28 per share to earnings of US$0.28 per share over the same period. This puts the...
NasdaqGS:CRSR
NasdaqGS:CRSRTech

Corsair Gaming (CRSR) Is Up 31.3% After First-Ever US$50 Million Buyback And Profitable Q4

Corsair Gaming, Inc. reported its fourth-quarter and full-year 2025 results on 12 February 2026, with Q4 sales of US$436.86 million and net income of US$25.79 million, alongside its first-ever US$50 million share repurchase authorization. While full-year 2025 still showed a net loss of US$16.16 million, the sharp improvement from the prior year and initiation of buybacks highlight a focus on profitability and capital returns. Next, we'll examine how Corsair's strong Q4 profitability and...
NYSE:BOOT
NYSE:BOOTSpecialty Retail

Boot Barn Expansion Push Tests Store Economics And Earnings Potential

Boot Barn Holdings (NYSE:BOOT) has outlined an aggressive new store expansion plan. The company is targeting a long term goal of 1,200 locations across the United States. Management has highlighted strong unit economics for new stores and is aiming for sustained double digit annual unit growth. Boot Barn Holdings, which focuses on western and work related apparel, footwear, and accessories, is moving into a larger phase of its store rollout. For you as an investor, the shift from regional...
TSX:ALYA
TSX:ALYAIT

Alithya Group Q3 2026 C$30.9m Loss Tests Bullish Profitability Narrative

Alithya Group (TSX:ALYA) has just posted its Q3 2026 numbers, with recent quarterly revenue sitting around C$124.3 million in Q2 2026 and basic EPS at a loss of C$0.32. Earlier quarters over the past year have ranged from C$111.5 million to C$125.3 million in revenue and basic EPS from a C$0.08 profit to a C$0.04 loss. Over the trailing twelve months to Q2 2026, revenue has hovered around C$468.7 million to C$489.5 million and basic EPS has swung between a small profit of C$0.01 and a loss of...
ASX:ARF
ASX:ARFSpecialized REITs

A Look At Arena REIT (ASX:ARF) Valuation After Strong Half Year Earnings Growth

Arena REIT (ASX:ARF) just released half year results and outlined fresh acquisition plans, putting its earnings profile and capital recycling approach in the spotlight for investors watching social infrastructure real estate. See our latest analysis for Arena REIT. The latest half year earnings update and renewed acquisition push have come alongside a 1 day share price return of 3.17% and a 7 day share price return of 3.47%. The 1 year total shareholder return of a 3.68% decline contrasts...